Long-term auditory complications after childhood cancer: A report from the Swiss Childhood Cancer Survivor Study
Annette Weiss
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorGrit Sommer
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorRahel Kasteler
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorKatrin Scheinemann
Division of Pediatric Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland
Search for more papers by this authorMichael Grotzer
Department of Pediatric Oncology, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
Search for more papers by this authorMartin Kompis
Department of ENT, Head and Neck Surgery, University Hospital Bern, University of Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Claudia E. Kuehni
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Correspondence
Claudia E. Kuehni, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland.
Email: [email protected]
Search for more papers by this authorfor the Swiss Pediatric Oncology Group (SPOG)
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Swiss Pediatric Oncology Group (SPOG) Scientific Committee: Prof. Dr. med. R. Ammann, Bern; Dr. med. R. Angst, Aarau; PD Dr. med. M. Ansari, Geneva; PD Dr. med. M. Beck Popovic, Lausanne; Dr. med. E. Bergstraesser, Zurich; Dr. med. P. Brazzola, Bellinzona; Dr. med. J. Greiner, St. Gallen; Prof. Dr. med. M. Grotzer, Zurich; Dr. med. H. Hengartner, St. Gallen; Prof. Dr. med. T. Kuehne, Basel; Prof. Dr. med. K. Leibundgut, Bern; Prof. Dr. med. F. Niggli, Zurich; PD Dr. med. J. Rischewski, Lucerne; Prof. Dr. med. N. von der Weid, Basel.
Search for more papers by this authorAnnette Weiss
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorGrit Sommer
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorRahel Kasteler
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Search for more papers by this authorKatrin Scheinemann
Division of Pediatric Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland
Search for more papers by this authorMichael Grotzer
Department of Pediatric Oncology, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
Search for more papers by this authorMartin Kompis
Department of ENT, Head and Neck Surgery, University Hospital Bern, University of Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Claudia E. Kuehni
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Correspondence
Claudia E. Kuehni, Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland.
Email: [email protected]
Search for more papers by this authorfor the Swiss Pediatric Oncology Group (SPOG)
Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
Swiss Pediatric Oncology Group (SPOG) Scientific Committee: Prof. Dr. med. R. Ammann, Bern; Dr. med. R. Angst, Aarau; PD Dr. med. M. Ansari, Geneva; PD Dr. med. M. Beck Popovic, Lausanne; Dr. med. E. Bergstraesser, Zurich; Dr. med. P. Brazzola, Bellinzona; Dr. med. J. Greiner, St. Gallen; Prof. Dr. med. M. Grotzer, Zurich; Dr. med. H. Hengartner, St. Gallen; Prof. Dr. med. T. Kuehne, Basel; Prof. Dr. med. K. Leibundgut, Bern; Prof. Dr. med. F. Niggli, Zurich; PD Dr. med. J. Rischewski, Lucerne; Prof. Dr. med. N. von der Weid, Basel.
Search for more papers by this authorAbstract
Background
Auditory complications are an adverse event of childhood cancer treatment, especially common in children treated with platinum chemotherapy or cranial radiation. Variation between diagnostic childhood cancer groups has rarely been studied, and we do not know if the burden of auditory complications has changed over the last decades.
Procedure
Within the Swiss Childhood Cancer Survivor Study, we sent a questionnaire to all survivors who were diagnosed at age 16 years or less between 1976 and 2005. We compared prevalence of self-reported hearing loss and tinnitus between all diagnostic childhood cancer groups and siblings, used multivariable logistic regression to analyze the effect of treatment-related factors on hearing loss, and compared the cumulative incidence of hearing loss between different periods of cancer diagnosis.
Results
Prevalence of self-reported hearing loss was higher in survivors (10%) than in siblings (3%, P < 0.001), and highest in survivors of central nervous system tumors (25%). Significant risk factors were treatment with platinum compounds (carboplatin: odds ratio [OR] 2.4; cisplatin: OR 9.4), cranial radiation (>29 Gy: OR >1.7), or brain surgery (OR 2.2). Children diagnosed in 1986–1995, when platinum compounds came into widespread use, had a significantly higher cumulative incidence of hearing loss than those diagnosed in 1976–1985. In the most recent period, 1996–2005, the risk decreased again, both for patients treated with platinum compounds and with cranial radiation.
Conclusions
Our data show that the burden of hearing loss has stabilized in recently treated survivors, suggesting that survivors have benefited from new treatment regimens that use less ototoxic radiation and more carefully dosed platinum compounds.
Supporting Information
| Filename | Description |
|---|---|
| SupplementarydataAuditorycomplicationsWeissFIRSTLOOK.docx76.4 KB | SUPPLEMENTARY FIGURE S1 Response rates in the SCCSS |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Landier W. Ototoxicity and cancer therapy. Cancer. 2016; 122(11): 1467–1658.
- 2Langer T, am Zehnhoff-Dinnesen A, Radtke S, Meitert J, Zolk O. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013; 34(8): 458–469.
- 3Rybak LP, Mukherjea D, Jajoo S, Ramkumar V. Cisplatin ototoxicity and protection: Clinical and experimental studies. Tohoku J Exp Med. 2009; 219(3): 177–186.
- 4Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 2007; 226(1–2): 157–167.
- 5Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: A consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston ototoxicity scale. J Clin Oncol. 2012; 30(19): 2408–2417.
- 6Hua C, Bass JK, Khan R, Kun LE, Merchant TE. Hearing loss after radiotherapy for pediatric brain tumors: Effect of cochlear dose. Int J Radiat Oncol Biol Phys. 2008; 72(3): 892–899.
- 7Lee T-F, Yeh S-A, Chao P-J, et al. Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy. Radiat Oncol. 2015; 10(1): 1–8.
- 8Gurney JG, Tersak JM, Ness KK, Landier W, Matthay KK, Schmidt ML, Children's Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: A report from the Children's Oncology Group. Pediatrics. 2007; 120(5): e1229–e1236.
- 9Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005; 23(34): 8588–8596.
- 10Lieu JE, Tye-Murray N, Karzon RK, Piccirillo JF. Unilateral hearing loss is associated with worse speech-language scores in children. Pediatrics. 2010; 125(6): e1348–e1355.
- 11Orgel E, O'Neil SH, Kayser K, et al. Effect of sensorineural hearing loss on neurocognitive functioning in pediatric brain tumor survivors. Pediatr Blood Cancer. 2016; 63(3): 527–534.
- 12Whelan K, Stratton K, Kawashima T, et al. Auditory complications in childhood cancer survivors: A report from the childhood cancer survivor study. Pediatr Blood Cancer. 2011; 57(1): 126–134.
- 13Moeller BJ, Chintagumpala M, Philip JJ, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. Radiat Oncol. 2011; 6: 58.
- 14Huang E, Teh BS, Strother DR, et al. Intensity-modulated radiation therapy for pediatric medulloblastoma: Early report on the reduction of ototoxicity. Int J Radiat Oncol Biol Phys. 2002; 52(3): 599–605.
- 15Packer RJ, Gurney JG, Punyko JA, et al. Long-term neurologic and neurosensory sequelae in adult survivors of a childhood brain tumor: Childhood cancer survivor study. J Clin Oncol. 2003; 21(17): 3255–3261.
- 16Christopherson KM, Rotondo RL, Bradley JA, et al. Late toxicity following craniospinal radiation for early-stage medulloblastoma. Acta Oncol. 2014; 53(4): 471–480.
- 17Sivaprakasam P, Gupta AA, Greenberg ML, Capra M, Nathan PC. Survival and long-term outcomes in children with hepatoblastoma treated with continuous infusion of cisplatin and doxorubicin. J Pediatr Hematol Oncol. 2011; 33(6): e226–e230.
- 18Cheuk DK, Billups CA, Martin MG, et al. Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma. Cancer. 2011; 117(1): 197–206.
- 19Gurney JG, Ness KK, Rosenthal J, Forman SJ, Bhatia S, Baker KS. Visual, auditory, sensory, and motor impairments in long-term survivors of hematopoietic stem cell transplantation performed in childhood: Results from the Bone Marrow Transplant Survivor study. Cancer. 2006; 106(6): 1402–1408.
- 20Kuehni CE, Rueegg CS, Michel G, et al., Swiss Paediatric Oncology Group. Cohort profile: The Swiss Childhood Cancer Survivor Study. Int J Epidemiol. 2012; 41(6): 1553–1564.
- 21Michel G, von der Weid NX, Zwahlen M, Adam M, Rebholz CE, Kuehni CE, Swiss Childhood Cancer Registry, Swiss Paediatric Oncology Group Scientific Committee. The Swiss Childhood Cancer Registry: Rationale, organisation and results for the years 2001–2005. Swiss Med Wkly. 2007; 137(35–36): 502–509.
- 22Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. Cancer. 2005; 103(7): 1457–1467.
- 23Yancey A, Harris MS, Egbelakin A, Gilbert J, Pisoni DB, Renbarger J. Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients. Pediatr Blood Cancer. 2012; 59(1): 144–148.
- 24Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004; 75(1): 45–49.
- 25Wengenroth L, Rueegg CS, Michel G, et al. Life partnerships in childhood cancer survivors, their siblings, and the general population. Pediatr Blood Cancer. 2014; 61(3): 538–545.
- 26Stekhoven DJ, Buhlmann P. MissForest—Non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012; 28(1): 112–118.
- 27Merchant TE, Gould CJ, Xiong X, et al. Early neuro-otologic effects of three-dimensional irradiation in children with primary brain tumors. Int J Radiat Oncol Biol Phys. 2004; 58(4): 1194–1207.
- 28Cohen LE, Gordon JH, Popovsky EY, et al. Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems. Bone Marrow Transplant. 2014; 49(4): 502–508.
- 29Oue T, Miyoshi Y, Hashii Y, et al. Problems during the long-term follow-up after surgery for pediatric solid malignancies. Eur J Pediatr Surg. 2015; 25(1): 123–127.
- 30Guillaume DJ, Knight K, Marquez C, Kraemer DF, Bardo DM, Neuwelt EA. Cerebrospinal fluid shunting and hearing loss in patients treated for medulloblastoma. J Neurosurg Pediatr. 2012; 9(4): 421–427.
- 31Qaddoumi I, Bass JK, Wu J, et al. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 2012; 30(10): 1034–1041.
- 32Kolinsky DC, Hayashi SS, Karzon R, Mao J, Hayashi RJ. Late onset hearing loss: A significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol. 2010; 32(2): 119–123.
- 33Konrad-Martin D, Helt WJ, Reavis KM, et al. Ototoxicity: Early detection and monitoring. ASHA Leader. 2005; 10(7): 1–14.
- 34Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol. 2005; 6(9): 649–658.
- 35Polkinghorn WR, Dunkel IJ, Souweidane MM, et al. Disease control and ototoxicity using intensity-modulated radiation therapy tumor-bed boost for medulloblastoma. Int J Radiat Oncol Biol Phys. 2011; 81(3): e15–e20.
- 36Packer RJ, Goldwein J, Nicholson HS, et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol. 1999; 17(7): 2127–2136.
- 37Dhall G, Grodman H, Ji L, et al. Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the “Head Start” I and II protocols. Pediatr Blood Cancer. 2008; 50(6): 1169–1175.
- 38Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006; 24(25): 4202–4208.
- 39Bass JK, Knight KR, Yock TI, Chang KW, Cipkala D, Grewal SS. Evaluation and management of hearing loss in survivors of childhood and adolescent cancers: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2016; 63(7): 1152–1162.
- 40Sindhusake D, Mitchell P, Smith W, et al. Validation of self-reported hearing loss. The Blue Mountains Hearing Study. Int J Epidemiol. 2001; 30(6): 1371–1378.
- 41Schoot RA, Theunissen EA, Slater O, et al. Hearing loss in survivors of childhood head and neck rhabdomyosarcoma: A long-term follow-up study. Clin Otolaryngol. 2016; 41(3): 276–283.
